Cyteir Therapeutics
Cyteir Therapeutics, a company based in Lexington, MA, has initiated a cash liquidating distribution of approximately $115.94 million to its stockholders as part of its dissolution process.
Liquidating Distribution
Cyteir Therapeutics has initiated a cash liquidating distribution totaling $115,939,606.84. This distribution is available to stockholders of record as of March 20, 2024. Each stockholder will receive a pro rata portion of this distribution, specifically $3.16 per share held. This action is part of the company's Plan of Complete Liquidation and Dissolution approved by the board of directors and stockholders on November 16, 2023.
Plan of Complete Liquidation and Dissolution
The Plan of Complete Liquidation and Dissolution for Cyteir Therapeutics was approved by both the board of directors and its stockholders during a special meeting on November 16, 2023. This plan outlines the steps the company will take to dissolve and distribute its remaining assets to its stockholders. The process includes the cash liquidating distribution to stockholders and the subsequent dissolution of the company.
Certificate of Dissolution
Cyteir Therapeutics filed a certificate of dissolution with the Secretary of State of the State of Delaware on March 20, 2024. This filing initiates the formal dissolution of the company in accordance with the General Corporation Law of the State of Delaware. The certificate of dissolution signifies the final step in the company's planned liquidation process.
Company Location
Cyteir Therapeutics is located at 99 Hayden Ave., Building B, Suite 450, Lexington, MA 02421. This address serves as the company's headquarters, housing its operational activities until the completion of the liquidation and dissolution process.